Canada Pension Plan Investment Board Purchases New Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Canada Pension Plan Investment Board purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 106,800 shares of the company’s stock, valued at approximately $16,086,000. Canada Pension Plan Investment Board owned approximately 0.32% of TransMedics Group at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TMDX. Wasatch Advisors LP purchased a new position in shares of TransMedics Group in the first quarter valued at $32,162,000. Vaughan Nelson Investment Management L.P. purchased a new position in shares of TransMedics Group in the 2nd quarter worth $39,862,000. First Light Asset Management LLC increased its holdings in shares of TransMedics Group by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after buying an additional 136,217 shares during the last quarter. F M Investments LLC purchased a new stake in shares of TransMedics Group during the 2nd quarter valued at about $10,957,000. Finally, Eventide Asset Management LLC lifted its holdings in shares of TransMedics Group by 7.4% in the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after acquiring an additional 68,884 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the subject of several analyst reports. Needham & Company LLC initiated coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective for the company. TD Cowen lifted their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Morgan Stanley lifted their price target on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Piper Sandler increased their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.44.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,247 shares of company stock worth $9,650,880. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Stock Performance

TransMedics Group stock opened at $159.50 on Tuesday. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a market capitalization of $5.25 billion, a PE ratio of -469.12 and a beta of 1.99. The company has a 50 day moving average price of $155.95 and a 200-day moving average price of $130.14. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. During the same period in the prior year, the business earned ($0.03) EPS. The business’s revenue for the quarter was up 117.7% compared to the same quarter last year. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.